In its new guidance (PDF), health technology assessment (HTA) agency NICE notes that, at the moment, patients with chronic ITP who do not respond to or cannot tolerate TPO-RA drugs are treated ...

Disappointingly, a third drug also tested in the study failed to show additive efficacy in RA when combined with tofacitinib ...

The US Food and Drug Administration (FDA ... is a thrombopoietin receptor agonist (TPO-RA) that does not compete with thrombopoietin (TPO) for receptor binding. It functions by stimulating ...

The following is a summary of “Thyroid peroxidase antibodies and their role in predicting outcomes in Graves’ disease ...